human aortic vascular smooth muscle cells vsmcs Search Results


human brain vascular smooth muscle cells hbvsmcs  (Innoprot Inc)
90
Innoprot Inc human brain vascular smooth muscle cells hbvsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Brain Vascular Smooth Muscle Cells Hbvsmcs, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+aortic+vascular+smooth+muscle+cells+vsmcs/pmc08444498-129-3-13?v=Innoprot+Inc
Average 90 stars, based on 1 article reviews
human brain vascular smooth muscle cells hbvsmcs - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
human coronary vascular endothelial cells (hcvecs)  (Lonza)
90
Lonza human coronary vascular endothelial cells (hcvecs)
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Coronary Vascular Endothelial Cells (Hcvecs), supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+aortic+vascular+smooth+muscle+cells+vsmcs/pmc04107099-139-0-9?v=Lonza
Average 90 stars, based on 1 article reviews
human coronary vascular endothelial cells (hcvecs) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
human aortic vascular smooth muscle cells (vsmcs)  (ScienCell)
90
ScienCell human aortic vascular smooth muscle cells (vsmcs)
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Aortic Vascular Smooth Muscle Cells (Vsmcs), supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+aortic+vascular+smooth+muscle+cells+vsmcs/pmc03248008-43-0-12?v=ScienCell
Average 90 stars, based on 1 article reviews
human aortic vascular smooth muscle cells (vsmcs) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
human vascular smooth muscle cells (vsmcs)  (Kurabo industries)
90
Kurabo industries human vascular smooth muscle cells (vsmcs)
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Vascular Smooth Muscle Cells (Vsmcs), supplied by Kurabo industries, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+aortic+vascular+smooth+muscle+cells+vsmcs/pm28131048-81-0-6?v=Kurabo+industries
Average 90 stars, based on 1 article reviews
human vascular smooth muscle cells (vsmcs) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
human primary vascular smooth muscle cells (vsmc)  (BioResource International Inc)
90
BioResource International Inc human primary vascular smooth muscle cells (vsmc)
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Primary Vascular Smooth Muscle Cells (Vsmc), supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+aortic+vascular+smooth+muscle+cells+vsmcs/pm40084813-173-0-30?v=BioResource+International+Inc
Average 90 stars, based on 1 article reviews
human primary vascular smooth muscle cells (vsmc) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


MFG-E8 expression in HBVSMCs after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001

Journal: Acta Neuropathologica Communications

Article Title: MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy

doi: 10.1186/s40478-021-01257-9

Figure Lengend Snippet: MFG-E8 expression in HBVSMCs after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001

Article Snippet: Primary cultures of human brain vascular smooth muscle cells (HBVSMCs) were obtained from Innoprot (Derio, Bizkaia, Spain).

Techniques: Expressing, Immunocytochemistry, Western Blot, Transfection